Pfizer Gets Final EU Approval For Biosimilar Bevacizumab
Executive Summary
Pfizer has received a pan-European marketing authorization for its Zirabev biosimilar bevacizumab, a rival to Genentech’s Avastin. The nod marks Pfizer’s second European approval for an oncology biosimilar.
You may also be interested in...
Dr Reddy’s Strengthens European Position With UK Bevacizumab Launch
Dr Reddy’s made a biosimilar debut in the UK with its off-patent version of Roche’s Avastin, which reinforces the company’s “commitment to bring more biosimilar” products to market.
Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown
Samsung Bioepis has received a pan-European endorsement from the CHMP for its Aybintio bevacizumab biosimilar. The nod follows two previous European Avastin biosimilar approvals, with market formation believed to be imminent.
AryoGen Bevacizumab Biosimilar Compares To Avastin
Iranian player AryoGen has received a boost after a recent study revealed that the firm’s bevacizumab biosimilar was non-inferior to reference product Avastin terms of efficacy and tolerability.